Xcell Therapeutics

Since their inception in 2015, Xcell Therapeutics has focused on creating a better future for humanity through ethical science. After 10 years of research, they made a breakthrough with the development of CellCor™, a serum-free, chemically defined media composed of over 200 known compounds, free from animal or plant-derived components. Currently, their team of talented researchers is working on developing proliferation media for various animal cell types, using only ethical technologies and tools. Xcell Therapeutics aims to become a leader in regenerative medicine within the next 10 years, building a world where life sciences innovations are as ethical as they are revolutionary. They operate a GMP production facility in Yongin, with an annual production rate of 100,000 liters, and are working towards obtaining 510(K) approval. With a vision for 2025, they strive to become a leading manufacturer in the global regenerative medicine industry, aiming to improve human longevity and contribute to the planet’s well-being.

More information at xcell.media.